Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) : Episode 17

Opinion

Video

May 17, 2024

Phase 2 ATLEP Trial Results

The panel discusses the recently published phase 2 ATLEP trial, which analyzed PD-L1 expression in anaplastic thyroid cancer.

EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends

EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer

EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer

EP: 4.Predisposition for Patients Developing DTC: Age and Gender

EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management

EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

EP: 7.The Importance of Thyroidectomy in DTC Patient Care

EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression

EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned

EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy

EP: 12.Exploring Real-World Evidence Presented at ATA 2023

EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC

EP: 14.Toxicity Profiles for DTC Guidelines Therapies

EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment

EP: 16.Neoadjuvant Approach in RAI-R-DTC

EP: 17.Phase 2 ATLEP Trial Results

EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights

Related Videos

2 expert is featured in this series.

4 experts are featured in this series.

2 experts in this video

2 experts in this video

Related Content

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Related Content

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Latest Conference Coverage

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.